
Susana M. Campos, MD, discusses her thoughts on the biggest advancements in ovarian cancer in 2018. PARP inhibitors are great at putting these patients in remission; however, the challenge with this lies in keeping them in remission.

Your AI-Trained Oncology Knowledge Connection!


Published: November 8th 2018 | Updated: